Meeting
2016 ASCO Annual Meeting
Risk of HER2-positive breast cancer among germline CHEK2 mutation carriers with breast cancer.
Authors
Chethan Ramamurthy
Fox Chase Cancer Center, Philadelphia, PA
Chethan Ramamurthy , Raji Shameem , Andrea Forman , Jill S Dolinsky , Virginia Speare , Rachel E. McFarland , Wafik S. El-Deiry , Michael J. Hall , Mary Beryl Daly , Lori J. Goldstein , Elias Obeid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Genetics, and Epidemiology
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Genetics
Citation
J Clin Oncol 34, 2016 (suppl; abstr 1539)
DOI
10.1200/JCO.2016.34.15_suppl.1539
Abstract #
1539
Poster Bd #
362
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Development and validation of a residual risk score to predict breast cancer risk in unaffected women negative for mutations on a multi-gene hereditary cancer panel.
First Author: Elisha Hughes
Poster
2017 ASCO Annual Meeting
Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.
First Author: Allison W. Kurian
Poster
2017 ASCO Annual Meeting
Expanded yield of multiplex panel testing in fully accrued prospective trial.
First Author: Gregory Idos
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei